Table 1

Overall, Anemia, P Value No Anemia, P

n=2138 n= 796 (37.20%) n= 1342 (62.80%) Value

CABG PCI CABG (n=524) PCI

(n=392) (n=404) (n=818)
Baseline characteristics

Age (years), mean ± SD 63.7 ± 10.2 62.6±9.9 64.4 ±11.1 0.007 60.7 ± 9.7 65.9 ± 9.6 < 0.001

Body mass index (kg/m2), mean ± SD 28.8 (5.10) 28.3 ± 5.2 29.4 ± 5.0 0.002 28.6 ± 5.3 29.2 ± 5.1 0.055

Gender (male), n (%) 1678 (78.5%) 343 (87.50%) 343 (84.90%) 0.288 441 (84.20%) 551 (67.40%) < 0.001

Smoker, n (%) 849 (39.7%) 155 (39.50%) 147 (36.40%) 0.359 215 (41.00%) 332 (40.60%) 0.872

Diabetes mellitus, n (%) 1468 (68.7%) 284 (72.40%) 280 (69.30%) 0.329 380 (72.50%) 524 (64.10%) 0.001

Hypertension, n (%) 1495 (70.4%) 272 (69.40%) 293 (73.60%) 0.188 364 (69.50%) 566 (70.00%) 0.847

Dyslipidemia, n (%) 1463 (69.0%) 280 (71.40%) 295 (74.30%) 0.363 362 (69.10%) 526 (65.10%) 0.132

Congestive heart failure, n (%) 261 (12.2%) 34 (8.70%) 57 (14.10%) 0.016 31 (5.90%) 139 (17.00%) < 0.001

Peripheral arterial disease, n (%) 246 (11.5%) 28 (7.10%) 48 (11.90%) 0.023 34 (6.50%) 136 (16.60%) < 0.001

Coronary artery disease, n (%) 895 (41.9%) 141 (36.00%) 198 (49.00%) < 0.001 185 (35.30%) 371 (45.40%) < 0.001

Cerebral vascular accident, n (%) 222 (10.4%) 19 (4.80%) 48 (11.90%) < 0.001 24 (4.60%) 131 (16.00%) < 0.001

Chronic kidney disease, n (%) 437 (20.4%) 60 (15.30%) 99 (24.50%) 0.001 61 (11.60%) 217 (26.50%) < 0.001

Atrial fibrillation, n (%) 183 (8.6%) 14 (3.60%) 31 (7.70%) 0.012 15 (2.90%) 123 (15.00%) < 0.001

Family history of CAD, n (%) 399 (18.7%) 44 (11.20%) 97 (24.00%) < 0.001 66 (12.60%) 192 (23.50%) < 0.001

Previous myocardial infarction, n (%) 613 (28.7%) 89 (22.70%) 148 (36.60%) < 0.001 106 (20.20%) 270 (33.00%) < 0.001

EuroSCORE score, mean (SD) 3.9 (4.9) 3.3 ± 4.6 4.3 ± 6.0 0.012 3.2 ± 3.7 4.5 ± 4.9 < 0.001
Table 2

Overall, Anemia, P Value No Anemia, P

n=2138 n= 796 (37.20%) n= 1342 (62.80%) Value

CABG PCI CABG (n=524) PCI

(n=392) (n=404) (n=818)
Hospital presentation

Cardiac arrest, n (%) 70 (3.3%) 10 (2.60%) 19 (4.70%) 0.105 9 (1.70%) 32 (3.90%) 0.023

Type of cardiac arrest, n (%)

Ventricular fibrillation 39 (1.82%) 6 (1.53%) 7 (1.73%) >0.99 6 (1.15%) 20 (2.44%) 0.106

Pulseless electrical activity/Asystole 31 (1.44%) 4 (1.02%) 12 (2.97%) 0.074 3 (0.57%) 12 (1.47%) 0.183

Type of arrhythmia, n (%)

Atrial arrhythmia 48 (2.24%) 3 (0.77%) 13 (3.22%) 0.020 10 (1.91%) 22(2.69%) 0.464

Ventricular arrhythmia 81 (3.79%) 10 (29.41%) 24 (5.94%) 0.022 14 (29.80%) 33(70.20%) 0.224

Brady arrhythmia 17 (7.95%) 0 (0.00%) 4 (0.99%) 0.124 1 (0.19%) 12(1.47%) 0.021

Cardiogenic shock, n (%) 134 (6.3%) 1 (4.60%) 44 (10.90%) 0.001 15 (2.90%) 57 (7.00%) 0.001

ST-elevation myocardial infarction 389 (18.2%) 81 (20.70%) 68 (16.80%) 0.166 94 (17.90%) 146 (17.90%) 0.974

Non ST-elevation acute coronary syndrome 1084 (50.7%) 185 (47.20%) 189 (46.80%) 0.907 271 (51.70%) 439 (53.70%) 0.471

Stable coronary artery disease 277 (13.0%) 49 (12.50%) 46 (11.40%) 0.628 88 (16.80%) 94 (11.50%) 0.06

Silent ischemia/Others 387 (18.1%) 77 (19.60%) 101 (25.00%) 0.07 71 (13.50%) 138 (16.90%) 0.1

Left ventricular ejection fraction (%), 44.8 ± 11.6 45.9 ± 11.3 41.0 ± 11.5 < 0.001 47.9 ± 11.8 44.3 ± 11.1 0.001
mean (SD)
Creatinine clearance (ml/min), mean (SD) 76.2 ± 24.2 75.8 ± 22.3 70.5 ± 27.5 0.003 77.5 ± 21.4 78.4 ± 24.5 0.478
(pre-revascularization)
Table 3

Overall, P No Anemia, P
n=2138 Anemia, Value n= 1342 (62.80%) Value
n= 796 (37.20%)
CABG PCI CABG (n=524) PCI
(n=392) (n=404) (n=818)
Angiographic characteristics

Medina classification, n (%)

1,1,1 760 (35.5%) 140 (35.70%) 138 (34.20%) 0.6 190 (36.30%) 292 (35.70%) 0.8
1,0,1 162 (7.6%) 41 (10.50%) 106 (26.20%) 0.0001 51 (9.70%) 204 (24.90%) 0.0001
0,1,1 393 (18.4%) 49 (12.50%) 14 (3.50%) 0.0001 65 (12.40%) 34 (4.20%) 0.0001
1,1,0 402 (18.8%) 74 (18.90%) 75 (18.60%) 0.9 87 (16.60%) 157 (19.20%) 0.2
1,0,0 202 (9.4%) 33 (8.40%) 35 (8.70%) 0.8 53 (10.10%) 81 (9.90%) 0.9
0,1,0 160 (7.5%) 40 (10.20%) 22 (5.40%) 0.011 64 (12.20%) 34 (4.20%) 0.0001
0,0,1 21 (1.0%) 5 (1.30%) 2 (0.50%) 0.2 5 (1.00%) 9 (1.10%) 0.8
Lesion characteristics

Multivessel disease, n (%) 1202 (56.2%) 284 (72.40%) 192 (47.50%) 0.0001 339 (64.70%) 387 (47.30%) 0.0001
LAD, n (%) 287 (13.4%) 16 (4.10%) 78 (19.30%) 0.0001 20 (3.80%) 173 (21.10%) 0.0001
LCX, n (%) 35 (1.6%) 2 (0.50%) 7 (1.70%) 0.16 3 (0.60%) 23 (2.80%) 0.004
LAD and LCX, n (%) 327 (15.3%) 48 (12.20%) 71 (17.60%) 0.03 91 (17.40%) 117 (14.30%) 0.12
RCA, n (%) 10 (0.5%) 1 (0.30%) 3 (0.70%) 0.4 2 (0.40%) 4 (0.50%) 0.7
RCA + (LAD or LCX), n (%) 139 (6.5%) 28 (7.10%) 19 (4.70%) 0.15 47 (9.00%) 45 (5.50%) 0.01
Isolated left main disease, n (%) 138 (6.5%) 13 (3.30%) 34 (8.40%) 0.002 22 (4.20%) 69 (8.40%) 0.002
SYNTAX score
Low (≤ 22), n (%) 430 (20.2%) 60 (15.40%) 112 (27.80%) 0.0001 66 (12.70%) 192 (23.50%) 0.0001
Intermediate (23-32), n (%) 1107 (52.0%) 163 (41.90%) 193 (47.90%) 0.08 263 (50.70%) 488 (59.70%) 0.002
High (≥ 33), n (%) 592 (27.8%) 166 (42.70%) 98 (24.30%) 0.0001 190 (36.60%) 138 (16.90%) 0.0001
SYNTAX score, mean (SD) 29.0 (8.4) 31.0 ± 8.8 27.9 ± 8.7 0.001 30.8 ± 8.9 27.5 ± 7.3 0.001
Lesion location

Ostial/shaft only, n (%) 536 (25.1%) 123 (31.40%) 90 (22.30%) 0.003 178 (34.00%) 145 (17.70%) 0.0001
Distal bifurcation, n (%) 1602 (74.9%) 269 (68.60%) 314 (77.70%) 0.003 346 (66.00%) 673 (82.30%) 0.0001
Procedure
Intra-aortic ballon pump, n (%) 200 (9.4%) 51 (13.00%) 43 (10.60%) 0.301 51 (9.70%) 55 (6.70%) 0.047
Impella, n (%) 0 (0.00%) 6 (1.50%) 0.015 2 (0.40%) 6 (0.70%) 0.413
Table 4

Overall, Anemia, P Value No Anemia, P Value

n=2138 n= 796 (37.20%) n= 1342 (62.80%)

CABG PCI CABG PCI

(n=392) (n=404) (n=524) (n=818)
Discharge medications

ASA, 2010 0.065 0.153

357 (97.50%) 384 (99.20%) 485 (99.20%) 784 (99.70%)
n (%) (99.10%)
P2Y12 inhibitors, 1833 < 0.001 < 0.001
275 (75.10%) 387 (100.00%) 389 (79.60%) 782 (99.50%)
n (%) (90.40%)
Beta blocker, 1914 0.047 < 0.001
336 (91.80%) 369 (95.30%) 447 (91.40%) 762 (96.90%)
n (%) (94.40%)
Statin, 1934 < 0.001 < 0.001
330 (90.20%) 384 (99.20%) 443 (90.60%) 777 (98.90%)
n (%) (95.40%)
ACE inhibitors or ARB, 1516 < 0.001 < 0.001
190 (51.90%) 351 (90.70%) 277 (56.60%) 698 (88.80%)
n (%) (74.80%)
Medications during follow-
up
ASA, 1713 0.201 0.801
288 (96.30%) 340 (98.00%) 392 (96.80%) 693 (97.10%)
n (%) (97.10%)
P2Y12 inhibitors, 1129 < 0.001 516 < 0.001
149 (49.80%) 262 (75.50%) 202 (49.90%)
n (%) (64.00%) (72.30%)
Beta blocker, 1674 0.386 0.145
287 (96.00%) 328 (94.50%) 378 (93.30%) 681 (95.40%)
n (%) (94.80%)
Statin, 1727 0.009 0.219
284 (95.00%) 342 (98.60%) 396 (97.80%) 705 (98.70%)
n (%) (97.80%)
ACE inhibitors or ARB, 1332 < 0.001 < 0.001
166 (55.50%) 305 (87.90%) 242 (59.80%) 619 (86.70%)
n (%) (75.50%)
Table 5

Overall, Anemia, P Value No Anemia, P

n=2138 n= 796 (37.20%) n= 1342 (62.80%) Value

CABG PCI CABG PCI

(n=392) (n=404) (n=524) (n=818)
In-hospital events

Cardiac death, n (%) 81 (3.8%) 21 (5.3%) 14 (3.50%) 0.23 21 (4.00%) 25 (3.10%) 0.35

Non-cardiac death, n (%) 24 (1.1%) 10 (2.5%) 2 (0.50%) 0.02 7 (1.3%) 5 (0.60%) 0.23

Myocardial infarction, n (%) 73 (3.4%) 25 (6.40%) 6 (1.50%) < 0.001 30 (5.70%) 12 (1.50%) < 0.001

Target lesion revascularization, n (%) 11 (0.5%) 3 (0.80%) 1 (0.20%) 0.30 3 (0.60%) 4 (0.50%) 0.84

Target vessel revascularization, n (%) 15 (0.7%) 3 (0.80%) 2 (0.50%) 0.63 5 (1.00%) 5 (0.60%) 0.48

Cerebrovascular events, n (%) 48 (2.2%) 17 (4.30%) 8 (2.00%) 0.053 12 (2.30%) 11 (1.30%) 0.19

MACCE, n (%) 125 (5.8%) 37 (9.44%) 20 (5.00%) 0.006 34 (6.48%) 34 (4.20%) 0.10

Congestive heart failure, n (%) 89 (4.2%) 21 (5.40%) 18 (4.50%) 0.55 19 (3.60%) 31 (3.80%) 0.87

Major bleeding, n (%) 313 (14.6%) 74 (18.90%) 60 (14.90%) 0.13 75 (14.30%) 104 (12.70%) 0.41

Minor bleeding, n (%) 157 (7.3%) 38 (9.70%) 18 (4.50%) 0.004 52 (9.90%) 49 (6.00%) 0.008

Total mortality, n (%) 105 (4.9%) 31 (7.90%) 16 (4.00%) 0.02 28 (5.34%) 30 (3.70%) 0.14

Duration of hospital stay, median (IQR) 7 (9) 12 (8) 3 (6) < 0.001 11 (7) 3 (5) < 0.001
(Days)
Table 6

Pre-discharge hemoglobin level Overall, Very low Hb P Low Hb P Normal Hb P

n=2033 (<80 g/L for men & Value ( ≥80 & ≤119 g/L for women Value (≥130 g/L for men & ≥120 g/L Value
women) & ≤129 g/L for men) for women)
n=50 (2.5%) n=1018 (50%) n=965 (47.5%)
CABG PCI CABG PCI CABG PCI
(n=34) (n=16) (n=585) (n=433) (n=238) (n=727)
Follow-up events

Cardiac death, n (%) 14 (0.7%) 0 (0.0%) 1 (6.3%) 0.14 6 (1.03%) 0 (0.0%) 0.049 0 (0.0%) 7 (0.95%) 0.10

Non-cardiac death, n (%) 25 (1.2%) 2 (5.9%) 1 (6.3%) 0.9 10 (1.7%) 3 (0.7%) 0. 1 (0.4%) 8 (1.1%) 0.3

Myocardial infarction, n (%) 50 (2.5%) 4 (11.8%) 1 (6.3%) 0.9 13 (2.2%) 8 (1.8%) 0.6 9 (3.8%) 15 (2.1%) 0.14

Target lesion revascularization, 55 (2.7%) 6 (17.6%) 1 (6.3%) 0.28 9 (1.5%) 15 (3.5%) 0.04 3 (1.3%) 21 (2.9%) 0.17
n (%)
Target vessel revascularization, n (%) 60 (3%) 6 (17.6%) 1 (6.3%) 0.28 13 (2.2%) 15 (3.5%) 0.2 8 (3.4%) 17 (2.3%) 0.35

Cerebrovascular events, n (%) 31 (1.5%) 3 (8.8%) 0 (0.0%) 0.2 11 (1.9%) 6 (1.4%) 0.5 2 (0.8%) 9 (1.2%) 0.6

MACCE, n (%) 108 (5.3%) 12 (35.3%) 2 (12.5%) 0.1 25 (4.3%) 24 (5.5%) 0.35 8 (3.4%) 37 (5.1%) 0.10

Congestive heart failure, n (%) 415 (20.4%) 6 (17.6%) 6 (37.5%) 0.12 68 (11.6%) 145 (33.5%) 0.0001 46 (19.3%) 144 (19.8%) 0.8

Major bleeding, n (%) 8 (0.4%) 0 (0.0%) 0 (0.0%) 1 2 (0.3%) 1 (0.2%) 0.7 1 (0.4%) 4 (0.6%) 0.7

Minor bleeding, n (%) 32 (1.6%) 1 (2.9%) 0 (0.0%) 0.49 9 (1.5%) 5 (1.2%) 0.6 6 (2.5%) 11 (1.5%) 0.3

Total mortality, n (%) 39 (1.9%) 2 (5.9%) 2 (12.5%) 0.5 16 (2.7%) 3 (0.7%) 0.04 1 (0.4%) 15 (2.0%) 0.11

Median follow up time (IQR) 20 (27) 23 (24) 19 (33) 0.99 15 (26) 22 (26) 0.01 19 (31) 20 (25) 0.85
(months)